For moderate to severe ulcerative colitis (UC) in adult TNFi-IR patients1

Visit the U.S. site to learn
about the efficacy and
safety
of RINVOQ in gastroenterology
IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor
For moderate to severe ulcerative colitis (UC) in adult TNFi-IR patients1
Visit the U.S. site to learn
about the efficacy and
safety
of RINVOQ in gastroenterology
IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor
RINVOQ is indicated for the treatment of:
Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or other potent immunosuppressants such as azathioprine and cyclosporine.